Mynx Ace is designed to be used with patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5-F, 6-F, or 7-F procedural sheath.

It is estimated that more than 2.1 million of these procedures are conducted each year in the US, the company reported.

The commercial launch was announced as part of the annual meeting of the American College of Cardiology.

AccessClosure president and CEO Gregory Casciaro said the company is proud of the advantages Mynx Ace offers to femoral closure.

"Our continual drive toward innovations that provide physicians with outstanding products to improve patient care has allowed us to develop a closure device that provides consistent results, while continuing to offer the safety and security that has become synonymous with the Mynx name," Casciaro added.

Mynx closure devices are designed for patient comfort by providing gentle vascular closure without the use of cinching, sutures, or metal implants to enhance patient satisfaction and keep physicians on the leading edge of patient care.

With Mynx Ace, physicians can consistently close femoral artery access sites through a simple, three-step deployment system.

The Mynx Ace system uses AccessClosure’s Grip technology, which employs an extravascular sealant that actively adheres to the artery for safe and secure mechanical closure and dissolves within 30 days.

Image: AccessClosure Launches the Next-Generation Mynx Ace vascular closure device at Annual ACC Meeting. Photo: courtesy of AccessClosure Inc./ Business Wire